NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company . Shareholders who purchased shares ...

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in ...

The Trump administration said in a statement Monday that the new regulations include “critical and necessary steps to protect people from being enrolled in Marketplace ... That decision is already the ...

New and existing Checking and Savings members who have not previously enrolled in Direct Deposit ... Interest rates are variable and subject to change at any time. These rates are current as ...

The quadruple-masked, dose-finding trial enrolled 196 subjects across 38 sites in six nations. These individuals suffer from moderate-to-severe depression and have not responded to at least two ...

Credit: Thicha Satapitanon / Shutterstock. US-based clinical trial technology provider Mural Health Technologies has partnered with Irish healthcare intelligence company Icon to improve clinical trial ...

Rewriting Trump, review: Michael Wolff’s film can’t keep pace with its subject Sadly for this Sky Documentaries one-off, the chronicler of Donald Trump’s presidency turns out to be less ...

Navik (GD): Candidates must have passed Class 12 with Physics and Mathematics as mandatory subjects. Navik (DB): Candidates must have completed Class 10 from a recognised board. Gender ...

The Punjab government on Wednesday announced that it has made Punjabi a mandatory subject in all schools across the state, alleging it was removed from the Central Board of Secondary Education's ...

The trial enrolled subjects who had not previously been treated with a janus kinase inhibitor or other biologic therapies. Credit: zorukis/Shutterstock. Nektar Therapeutics has concluded target ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that the first subject treated ..